recent
year
decreas
global
mortal
improv
qualiti
life
among
signific
progress
child
adult
health
field
pediatr
infecti
diseas
remark
advanc
achiev
term
reduct
incid
childhood
infecti
diseas
associ
morbid
mortal
especi
true
vaccineprevent
diseas
immun
measl
haemophilu
influenza
type
b
pneumococci
meningococci
rotaviru
varicella
hepat
b
viru
hbv
infect
etc
dramat
decreas
burden
target
infect
high
lowincom
countri
global
challeng
control
hbv
dissemin
well
illustr
prevent
measur
could
hinder
seriou
cours
infecti
diseas
inde
case
hbv
infect
perinat
exposur
repres
import
mode
transmiss
lead
chronic
diseas
infect
newborn
follow
implement
mani
countri
univers
vaccin
babi
born
hbv
posit
mother
consider
modifi
epidemiolog
hbv
infect
worldwid
given
best
immunoprophylaxi
current
avail
hepat
b
vaccin
hepat
b
immun
globulin
perinat
hbv
infect
occur
among
infant
infect
mother
success
obtain
hbv
vaccin
well
mani
other
vaccin
campaign
led
consid
prevent
lifesav
immun
one
seven
greatest
achiev
pediatr
research
observ
last
four
decad
emphas
recent
review
addit
vaccin
prenat
screen
prevent
measur
improv
environment
condit
person
hygien
togeth
broaden
suppli
drinkabl
water
also
significantli
contribut
reduc
preval
burden
highli
transmiss
infect
ie
cholera
shigellosi
hepat
differ
part
world
old
principl
issu
chines
tradit
medicin
ounc
prevent
worth
pound
cure
achiev
real
signific
think
pediatr
infecti
diseas
recent
success
stori
prevent
mothertochild
transmiss
human
immunodefici
viru
hiv
well
illustr
keyston
concept
high
preval
region
univers
hiv
test
pregnant
women
combin
use
antiretrovir
therapi
also
avoid
breastfeed
schedul
cesarean
section
mother
high
risk
transmiss
permit
togeth
decreas
risk
perinat
transmiss
mani
countri
subsequ
impact
childhood
mortal
hand
manag
common
pediatr
infecti
diseas
also
complet
modifi
last
decad
aim
increas
therapeut
efficaci
also
lower
relat
complic
societ
cost
great
proport
pneumonia
urinari
tract
infect
treat
short
inpati
stay
even
fulli
ambulatori
basi
instead
long
pain
intraven
therapeut
cours
previous
recommend
even
deepseat
infect
septic
arthriti
osteomyel
formerli
associ
extend
period
hospit
manag
instanc
oral
ambulatori
treatment
short
day
hospit
stay
along
new
drug
avail
assess
pediatr
pharmacokinet
pk
pharmacodynam
pd
drug
properti
signific
insight
diagnost
procedur
trend
shorten
hospit
stay
improv
patient
comfort
decreas
risk
secondari
nosocomi
infect
avoid
overwhelm
hospit
cost
frontier
pediatricspediatr
infecti
diseas
section
priorit
abovement
concept
also
aim
look
forward
anticip
futur
challeng
pediatr
infecti
diseas
specialist
face
next
year
main
goal
guid
encourag
research
submit
paper
deal
present
futur
critic
area
research
outlin
despit
success
mani
immun
program
detail
caveat
dispar
vaccin
polici
remain
first
emphas
recent
world
health
organ
report
nearli
one
five
children
worldwid
receiv
routin
immun
vaccineprevent
diseas
lead
unaccept
inequ
besid
polit
econom
issu
provid
immun
world
requir
develop
less
expens
thermost
vaccin
formul
recent
achiev
lowcost
heatstabl
oral
bovin
pentaval
rotaviru
vaccin
produc
india
test
subsaharan
africa
among
infant
niger
efficaci
three
dose
schedul
sever
rotaviru
gastroenter
compar
measur
current
licens
rotaviru
vaccin
develop
countri
second
time
fund
dedic
develop
vaccin
pathogen
consid
ubiquit
human
killer
exist
vaccin
remain
disappoint
term
effect
influenza
pertussi
tuberculosi
malaria
new
candid
vaccin
emerg
diseas
zika
viru
ebola
viru
chikungunya
viru
middl
east
respiratori
syndrom
coronaviru
merscov
infect
also
need
wherea
latter
close
evalu
human
convinc
result
requir
among
adult
first
test
pediatr
subject
third
popul
scale
key
role
herd
immun
contribut
vaccin
effect
combin
dynam
circul
bacteria
render
mandatori
continu
evalu
vaccin
impact
diseas
epidemiolog
especi
true
look
replac
phenomenon
switch
bacteri
serotyp
other
observ
insid
nasopharyng
nich
univers
mass
vaccin
pneumococc
conjug
vaccin
fourth
matern
immun
repres
expand
field
investig
numer
new
scientif
hypothes
investig
see
next
section
eventu
besid
expect
convent
effect
diseas
incid
preval
author
recent
highlight
vaccin
also
produc
nonspecif
benefici
immunolog
effect
inde
strong
scientif
evid
suggest
certain
live
attenu
vaccin
bcg
measl
vaccin
reduc
allcaus
mortal
probabl
confer
crossprotect
addit
untarget
pathogen
surpris
fascin
hypothesi
definit
deserv
studi
elucid
reason
expert
john
hopkin
yale
univers
classifi
pediatr
immun
one
next
seven
great
prioriti
pediatr
research
face
part
world
return
old
diseas
pertussi
tuberculosi
measl
find
innov
strategi
prevent
therapi
essenti
recent
year
effort
limit
famili
spread
pertussi
young
infant
develop
addit
matern
immun
provid
adolesc
adult
addit
booster
dose
coupl
howev
effici
cocoon
strategi
pertussi
difficult
implement
neonat
vaccin
limit
exampl
defin
optim
time
matern
immun
pertussi
remain
controversi
measl
preval
europ
decreas
diseas
far
erad
reemerg
mani
countri
numer
outbreak
associ
sometim
lifethreaten
present
therefor
improv
clinic
awar
combin
epidemiolog
virolog
surveil
use
modern
laboratori
tool
effici
report
system
requir
global
erad
emerg
multiresist
bacteria
gramposit
cocci
gramneg
rod
mdr
tuberculosi
xdr
tuberculosi
etc
major
global
threat
past
year
mani
countri
report
first
time
arriv
carbapenemas
produc
rod
among
other
new
delhi
isol
klebsiella
pneumonia
escherichia
coli
worldwid
offer
treatment
opportun
pathogen
involv
invas
diseas
wherea
issu
alreadi
constitut
major
concern
adult
set
data
epidemiolog
optim
treatment
option
even
limit
pediatr
avoid
perman
extrapol
adult
data
need
wellconduct
pediatr
studi
assess
impact
variou
treatment
strategi
perform
adult
set
kind
studi
help
us
address
crucial
unansw
question
like
suitabl
antibiot
option
defin
pathogen
dosag
use
accord
age
group
optim
durat
therapi
etc
furthermor
problem
resist
fungal
viral
infect
neglect
increas
parallel
broader
use
immunosuppress
therapi
advanc
bone
marrow
solid
organ
transplant
new
antivir
drug
cmv
adenoviru
infect
recent
develop
obtain
instanc
compassion
use
offer
last
chanc
patient
suffer
dissemin
uncontrol
viral
diseas
data
children
remain
limit
case
seri
new
drug
seem
promis
use
worth
report
parallel
signific
insight
specif
immunotherapi
treat
dissemin
cmv
adenoviru
ebv
infect
transplant
patient
offer
encourag
reliabl
approach
improv
prognosi
seriou
ill
mention
section
proper
pediatr
clinic
trial
larg
sampl
size
encourag
rather
alway
base
manag
pediatr
patient
extrapol
adult
studi
import
field
pharmacolog
antimicrobi
still
mani
drug
includ
last
avail
antimicrobi
brought
market
without
pediatricspecif
label
pk
pd
data
lack
reliabl
pediatr
recommend
common
knowledg
drug
metabol
differ
among
age
group
bodi
surfac
also
variat
renal
hepat
drug
excret
therefor
find
optim
therapeut
dosag
offer
maximum
safeti
efficaci
challeng
children
particularli
neonat
even
follow
result
blood
drug
monitor
huge
differ
exist
look
exampl
metabol
excret
antifung
newborn
infant
compar
adult
broader
clinic
trial
therefor
warrant
determin
adequ
dosag
age
group
especi
youngest
addit
major
antifung
like
voriconazol
posaconazol
remain
indic
due
lack
safeti
data
restrict
therapeut
option
case
invas
central
nervou
system
fungal
infect
likewis
small
pediatr
studi
assess
best
dosag
new
antibiot
like
moxifloxacin
linezolid
paper
provid
suitabl
data
guid
choic
among
vast
antibiot
armamentarium
studi
children
need
compar
effici
differ
antibiot
schedul
morbid
mortal
prevent
recurr
infect
caus
common
suscept
bacteria
eg
mssa
field
emerg
infecti
diseas
merscov
enteroviru
zika
ebola
chikungunya
etc
also
utmost
import
recent
outbreak
creat
signific
import
threat
certain
region
world
requir
import
mobil
resourc
healthcar
worker
provid
care
infect
peopl
well
develop
diagnost
tool
new
drug
vaccin
set
new
outbreak
make
right
clinic
diagnosi
crucial
patient
also
allow
manag
epidem
rapid
confin
infect
peopl
therefor
public
reliabl
epidemiolog
data
base
wide
surveil
program
descript
encount
clinic
pattern
top
prioriti
enteroviru
infect
recent
emerg
major
viral
agent
region
world
although
viru
consid
mostli
benign
qualiti
clinic
laboratori
studi
delin
place
seriou
respiratori
central
nervou
system
pathogen
besid
common
cold
spontan
resolv
mening
infect
children
inde
present
acut
respiratori
failur
requir
icu
admiss
other
develop
acut
flaccid
paralysi
mimick
pattern
observ
polio
viru
infect
viral
infect
elicit
near
futur
definit
deserv
care
surveil
especi
sinc
neither
antivir
drug
vaccin
viru
current
avail
recent
advanc
pediatr
research
dramat
improv
surviv
immunocompromis
children
adolesc
howev
whether
immunosuppress
acquir
congenit
infecti
diseas
remain
major
caus
morbid
mortal
particular
popul
improv
manag
fungal
viral
infect
children
repres
top
prioriti
last
year
excit
discoveri
genet
mechan
underli
rare
primari
immunodefici
carri
lead
better
understand
extraordinari
vulner
present
patient
specif
pathogen
nontubercul
mycobacteria
salmonella
sp
etc
mendelian
nonmendelian
transmit
genet
syndrom
doubt
field
collabor
immunologist
genetician
pediatr
infecti
diseas
continu
grow
rapid
pace
follow
year
especi
regard
exponenti
develop
genom
sequenc
method
last
decad
august
primari
immunodefici
identifi
correspond
gene
mutat
sinc
defici
pathway
underli
syndrom
everi
day
increasingli
understood
sinc
signific
insight
made
gene
therapi
bone
marrow
transplant
new
hope
aris
manag
rare
lifethreaten
diseas
new
primari
immunodefici
syndrom
recent
describ
patient
present
recurr
lifethreaten
infect
also
autoinflammatori
manifest
neurodevelopment
delay
specif
syndrom
link
exampl
defect
gain
function
interferon
pathway
autoinflammatori
pattern
inaugur
even
uniqu
featur
diseas
serious
impair
patient
growth
qualiti
life
besid
field
congenit
immunodefici
scientist
increasingli
recogn
inflamm
cascad
play
crucial
role
symptomatolog
harbor
infect
patient
modern
concept
sustain
whether
disproportion
immun
host
respons
gener
signific
damag
addit
expect
pathogen
even
look
paradox
first
glanc
control
inflamm
case
integr
part
therapi
togeth
antimicrobi
avoid
treatment
failur
poor
outcom
immun
reconstitut
syndrom
observ
hivinfect
patient
well
illustr
concept
inde
worsen
clinic
cours
observ
antiretrovir
therapi
start
earli
sever
mycobacteri
fungal
infecti
episod
likewis
sound
studi
point
key
role
inflamm
morbid
mortal
relat
broad
rang
infect
like
tubercul
mening
cystic
fibrosi
meningococc
invas
diseas
burden
tropic
diseas
malaria
schistosomiasi
chaga
diseas
neglect
tropic
diseas
etc
substanti
remain
mani
year
despit
progress
vaccin
environment
prevent
measur
avail
treatment
wherea
impact
obvious
peak
lowincom
countri
tropic
diseas
also
encount
nonendem
countri
consequ
global
migrat
grow
proport
patient
origin
endem
region
immigr
refuge
rel
visit
friend
part
world
addit
tourist
travel
therefor
good
knowledg
epidemiolog
therapi
diseas
mandatori
clinician
tropic
nontrop
area
recent
use
artemisininbas
combin
therapi
act
consider
improv
manag
malaria
adult
children
howev
artemisinin
resist
occur
southeast
asia
late
treatment
failur
act
report
nonimmun
european
subject
due
subtherapeut
drug
concentr
technolog
progress
field
pediatr
infecti
diseas
tremend
abl
exampl
look
numer
pathogen
singl
small
respiratori
sampl
thank
dna
amplif
molecular
biolog
recent
progress
biomolecular
technolog
allow
among
other
rapid
detect
mutat
confer
antibiot
resist
effici
genotyp
method
even
sequenc
whole
genom
virul
organ
like
mrsa
esbl
gramneg
bacteria
mycobacterium
tuberculosi
open
door
new
target
therapeut
prevent
strategi
well
better
surveil
case
epidem
dissemin
cluster
epidem
curv
etc
although
import
modern
medicin
technolog
advanc
answer
challeng
face
wide
knowledg
semiolog
clinician
constant
awar
good
prescript
diagnost
tool
appropri
infect
control
measur
ever
crucial
era
place
patient
center
preoccup
guarante
ration
use
avail
resourc
far
old
fashion
qualiti
clinic
epidemiolog
studi
need
use
basic
tool
monitor
trend
diseas
incid
anticip
futur
epidem
excel
studi
carri
clinic
epidemiolog
viral
pathogen
caus
common
respiratori
infect
respiratori
syncyti
viru
influenza
adenoviru
etc
chapel
hill
north
carolina
still
preciou
inspir
daili
practic
conclus
keep
mind
nonexhaust
lectur
doubt
mani
excit
initi
area
investig
worth
attent
near
futur
also
definit
need
new
approach
implement
research
dissemin
knowledg
scienc
technolog
advanc
translat
polici
easili
avail
peopl
need
renew
editori
board
frontier
pediatricspediatr
infecti
diseas
readi
launch
discuss
new
opportun
scientif
research
look
forward
receiv
suggest
field
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
